StageMerger | Merged
BioClinica provides integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device development with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management, and clinical supply chain forecasting and optimization solutions. On December 10th, 2020, BioClinica merged with eResearchTechnology to form Clario.
Missing: BioClinica's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: BioClinica's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing BioClinica
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BioClinica is included in 6 Expert Collections, including Clinical Trials Tech.
Clinical Trials Tech
Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Clinical Trials Tech Market Map
This CB Insights Tech Market Map highlights 100+ clinical trials tech companies that are addressing 8 distinct technology priorities that pharmaceutical companies and CROs face.
Latest BioClinica News
Mar 13, 2023
News provided by Share this article Share this article BETHESDA, Md., March 13, 2023 /PRNewswire/ -- Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors. "We are thrilled to welcome John to our Board. He is a highly regarded leader in the pharmaceutical industry with extensive experience in clinical development and operations, strategic planning and business development," said Mark Clein, Chief Executive Officer of Precision Medicine Group. "His impressive qualifications make him uniquely qualified to appreciate the breadth of services offered across our organization and to provide valuable insight as we continue to expand our global footprint and integrated capabilities." Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and clinical research organizations (CROs). Dr. Hubbard was previously the President and Chief Executive Officer of Bioclinica, a leading provider of medical imaging, clinical technology, and development services. Under Dr. Hubbard's leadership, Bioclinica doubled in size, completed several acquisitions, and significantly expanded its customer base before being sold in October 2016. Before his work at Bioclinica, Dr. Hubbard was Senior Vice President and Worldwide Head of Development Operations at Pfizer, where he directed and led global clinical operations and development of more than 450 clinical studies per year. He also served as a member of the Portfolio Strategy and Investment Committee, Chair of the Enterprise Precision Medicine Steering Committee, and member of the Worldwide Research and Development Executive Leadership Team. Earlier, he was Group President of ICON plc's Global Clinical Research Services Division, one of the top five global CROs. Dr. Hubbard currently serves on the boards of several life science companies, including Advarra, Signant Health, Agile Therapeutics, and Science 37. He holds a PhD in cardiovascular psychophysiology and is a board-certified Diplomate in Applied Pharmacology and a Fellow of the American College of Clinical Pharmacology. "I am delighted to join PMG, a unique organization that brings together best-in-class expertise to propel both drug development and access, with the ultimate goal of delivering improved healthcare outcomes globally," said Dr. Hubbard. "Based on my firsthand experiences in the healthcare services space, I understand the critical value of efficiently executing complex clinical trials to improve their speed, cost and success rate, as well as the importance of translating science to engage stakeholders across the commercialization continuum. I am impressed by the breadth of services PMG offers its customers today and look forward to working with the management team and Board to build on this impressive foundation and support leading pharmaceutical and life sciences companies worldwide." About Precision Medicine Group Formed in 2012, Precision Medicine Group is a specialized services company supporting next-generation approaches to drug development and commercialization. Precision provides an integrated infrastructure that supports pharmaceutical and life science companies as they develop new products in the age of precision medicine. The company is headquartered in Bethesda, Maryland, with offices throughout North America and Europe. For more information, visit precisionmedicinegrp.com . Investor Contact
BioClinica Frequently Asked Questions (FAQ)
When was BioClinica founded?
BioClinica was founded in 1990.
Where is BioClinica's headquarters?
BioClinica's headquarters is located at 211 Carnegie Center Drive, Princeton.
What is BioClinica's latest funding round?
BioClinica's latest funding round is Merger.
Who are the investors of BioClinica?
Investors of BioClinica include Clario, H. Hemo, Water Street Healthcare Partners, JLL Partners and SV Health Investors.
Who are BioClinica's competitors?
Competitors of BioClinica include Greenphire and 2 more.
Compare BioClinica to Competitors
Medrio provides electronic data capture software for the process of clinical research. The platform supports phase I-IV trials, outcomes research, registries, retrospective chart reviews, and other clinical study needs.
Novadiscovery (Nova) is a health tech company using clinical trial simulation technology to predict drug efficacy and optimize clinical trial development. Nova combines mathematical models and artificial intelligence of diseases and drugs to simulate in silico clinical trials in virtual patient populations. The clinical trial simulation platform, Jinkō, helps biopharma companies by lowering cost of development, accelerating its pace and bringing drugs to market sooner.
Terray Therapeutics is a biotechnology company. The company has developed a novel screening and optimization platform (tArray) to develop invent treatments for intractable causes of human disease. The company is headquartered in Pasadena, California.
InSilicoTrials.com is a web-based platform, which provides a user-friendly computational modeling and simulation environment where many integrated easy-to-use in silico tools are readily available. The platform targets primarily users from the medical devices and pharmaceutical sectors. The company was founded in 2017 and is based in Trieste, Italy.
PointCross Life Sciences serves the Life Sciences R&D and regulatory data value chain with a focus on realizing the power of real-time data. Driven by the Xbiom platform, PointCross offers its global customers semantic data integration, advanced analytics, and visualization outputs, search and query functionality across highly stratified cohorts, and submission and validation workflows with a focus on quality and speed.
Collaborations Pharmaceuticals performs research and development on therapeutics for multiple rare and infectious diseases, and works with foundations, scientists and companies to enable drug discovery.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.